Chemoprevention of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced colon carcinogenesis by 1-O-hexyl-2,3,5-trimethylhydroquinone after initiation with 1,2-dimethylhydrazine in F344 rats

被引:14
作者
Futakuchi, M
Hirose, M
Imaida, K
Takahashi, S
Ogawa, K
Asamoto, M
Miki, T
Shirai, T
机构
[1] Nagoya City Univ, Sch Med, Dept Pathol 1, Mizuho Ku, Nagoya, Aichi 4678601, Japan
[2] Natl Inst Hlth Sci, Div Pathol, Tokyo 158, Japan
[3] Nippon Hypox Labs Inc, Div Toxicol & Metab, Yamanashi, Japan
关键词
D O I
10.1093/carcin/23.2.283
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study is to investigate the chemopreventive effects of the synthetic phenolic antioxidant 1-O-hexyl-2,3, 5-trimethylhydroquinone (HTHQ) on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-associated colon carcinogenesis in rats after initiation with 1,2-dimethylhydrazine (DMH) in male F344 rats. Groups of 20-22, 6-week-old male F344 rats were given four subcutaneous injections of 40 mg/kg body wt of DMH during the initial 4 weeks. They were then maintained on powdered basal diet containing 0.03% PhIP alone, PhIP together with 0.5 or 0.125% HTHQ, 0.5 or 0.125% HTHQ alone or basal diet for 32 weeks. A small number (1.1 +/- 1.1/rat) of colon tumors were induced by DMH treatment alone. After initiation with DMH, the number of colon tumors was greatly increased to 8.3 +/- 5.6 by the administration of PhIP. Additional treatment with HTHQ dose-dependently decreased the multiplicity of colon adenocarcinomas to 4.9 +/- 2.8 and 2.6 +/- 1.4 with 0.125 and 0.5%, respectively. This treatment similarly reduced atypical hyperplasias of the ventral prostate. Furthermore, HTHQ significantly reduced the multiplicity of duodenal adenocarcinomas induced by DMH + PhIP or DMH alone. Immunohistochemically, HTHQ was revealed to suppress PhIP-DNA adduct formation in the epithelial cells of the colon and prostate in a separate 2 weeks experiment. The present results clearly showed that HTHQ has chemopreventive potential for PhIP-associated colon and prostate carcinogenesis. The observed inhibition may largely be due to interference with PhIP-DNA adduct formation. In addition, HTHQ has been demonstrated to inhibit duodenal carcinogenesis in the post-initiation stage.
引用
收藏
页码:283 / 287
页数:5
相关论文
共 37 条
[1]  
Barbin A, 1999, IARC SCI PUBL, P303
[2]   RELATIONSHIP OF DNA-ADDUCTS DERIVED FROM 2-ACETYLAMINOFLUORENE TO CELL-PROLIFERATION AND THE INDUCTION OF RODENT LIVER AND BLADDER-TUMORS [J].
COHEN, SM ;
ELLWEIN, LB .
TOXICOLOGIC PATHOLOGY, 1995, 23 (02) :136-142
[3]   MEAT, COOKING METHODS AND COLORECTAL-CANCER - A CASE-REFERENT STUDY IN STOCKHOLM [J].
DEVERDIER, MG ;
HAGMAN, U ;
PETERS, RK ;
STEINECK, G ;
OVERVIK, E .
INTERNATIONAL JOURNAL OF CANCER, 1991, 49 (04) :520-525
[4]   RELATIONSHIP BETWEEN 7,12-DIMETHYL-TRIMETHYLBENZ(A)ANTHRACENE AND 7,8,12-TRIMETHYLBENZ[A]ANTHRACENE DNA ADDUCT FORMATION IN HEMATOPOIETIC ORGANS AND LEUKEMOGENIC EFFECTS [J].
FALZON, M ;
VU, VT ;
ROLLER, PP ;
THORGEIRSSON, SS .
CANCER LETTERS, 1987, 37 (01) :41-49
[5]  
Felton J S, 1995, Princess Takamatsu Symp, V23, P50
[6]   THE ISOLATION AND IDENTIFICATION OF A NEW MUTAGEN FROM FRIED GROUND-BEEF - 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE(PHIP) [J].
FELTON, JS ;
KNIZE, MG ;
SHEN, NH ;
LEWIS, PR ;
ANDRESEN, BD ;
HAPPE, J ;
HATCH, FT .
CARCINOGENESIS, 1986, 7 (07) :1081-1086
[7]   DOSE-DEPENDENCE OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]-PYRIDINE (PHIP) CARCINOGENICITY IN RATS [J].
HASEGAWA, R ;
SANO, M ;
TAMANO, S ;
IMAIDA, K ;
SHIRAI, T ;
NAGAO, M ;
SUGIMURA, T ;
ITO, N .
CARCINOGENESIS, 1993, 14 (12) :2553-2557
[8]   SYNERGISTIC ENHANCEMENT OF SMALL AND LARGE INTESTINAL CARCINOGENESIS BY COMBINED TREATMENT OF RATS WITH 5 HETEROCYCLIC AMINES IN A MEDIUM-TERM MULTIORGAN BIOASSAY [J].
HASEGAWA, R ;
TANAKA, H ;
TAMANO, S ;
SHIRAI, T ;
NAGAO, M ;
SUGIMURA, T ;
ITO, N .
CARCINOGENESIS, 1994, 15 (11) :2567-2573
[9]  
HAYATSU H, 1985, JPN J CANCER RES, V76, P445
[10]   Chemoprevention of heterocyclic amine-induced carcinogenesis by phenolic compounds in rats [J].
Hirose, M ;
Takahashi, S ;
Ogawa, K ;
Futakuchi, M ;
Shirai, T ;
Shibutani, M ;
Uneyama, C ;
Toyoda, K ;
Iwata, H .
CANCER LETTERS, 1999, 143 (02) :173-178